Metaplastic Breast Cancer (MSK,NPJ Breast Cancer 2021)

Summary

Metaplastic Breast Cancer (MSK,NPJ Breast Cancer 2021) is a study catalogued by cBioPortal DataHub under the cancer-type code mbc. EvidenceHelix groups it with breast studies.

Study description

Targeted or whole-exome sequencing of 19 Metaplastic Breast Cancer tumor/normal pairs.

Text as published in the source's study metadata.

Citation & PubMed

Edaise M et al. NPJ Breast Cancer 2021

Linked PubMed records: PMID 33863915

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

mbc_msk_2021

Short name

MBC (MSK, 2021)

Source cancer-type code

mbc

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Edaise M et al. NPJ Breast Cancer 2021

• PubMed record 33863915 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)

  Whole exome sequencing of 12 breast AdCCs.

  BreastMSK studiesSource code acbcPubMed 1

• Breast Cancer (MSK, Cancer Cell 2018)

  Targeted Sequencing of tumor/normal sample pairs from 1918 Breast cancers.

  BreastMSK studiesSource code breastPubMed 1

• Breast Cancer (MSK, Clinical Cancer Res 2020)

  Whole-exome and MSK-IMPACT sequencing of 60 tumor/normal matched samples.

  BreastMSK studiesSource code brcaPubMed 1

• Breast Cancer (MSK, Nature Cancer 2020)

  Targeted sequencing of pre- and post-treatment tumor/cfDNA samples from 51 Breast Cancer patients to understand the mechanisms of resistance to Alepelisib.

  BreastMSK studiesSource code breastPubMed 1

• Breast Cancer (MSK, NPJ Breast Cancer 2019)

  Targeted Sequencing of buparlisib + letrozole and alpelisib + letrozole-treated metastatic ER+ unmatched breast tumors.

  BreastMSK studiesSource code brcaPubMed 1

• Breast Invasive Lobular Carcinoma (MSK, NPJ Precis Oncol 2024)

  Targeted Sequencing of 25 breast invasive lobular carcinoma tumors lacking CDH1 bi-allelic genetic alterations, and their matched normals via MSK-IMPACT.

  BreastMSK studiesSource code breastPubMed 1

• Juvenile Papillomatosis and Breast Cancer (MSK,J Pathol. 2015)

  Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma.

  BreastMSK studiesSource code brcaPubMed 1

• MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)

  MSK-IMPACT targeted sequencing of 145 breast tumors with matched normal samples.

  BreastMSK studiesSource code brcaPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.